Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 1 9Phase 3 6Phase 1/2 6Phase EARLY_PHASE1 2

Status

Completed 2Active not recruiting 2Terminated 1Enrolling by invitation 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Skin Neoplasms 1Motor Activity 1Melanoma 1Lymphoma, B-Cell 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 8Nivolumab 7Magnetic Resonance Spectroscopy 7Radiotherapy 6Biopsy 4Temozolomide 3Specimen Handling 3Irinotecan 3Ipilimumab 3Fluorodeoxyglucose F18 3Dexamethasone 3Bevacizumab 3venetoclax 2niraparib 2gallium 68 PSMA-11 2durvalumab 2avelumab 2Tobacco Use Cessation Devices 2Standard of Care 2Rituximab 2Positron-Emission Tomography 2Positron Emission Tomography Computed Tomography 2Paclitaxel 2Neoadjuvant Therapy 2Metastasectomy 2Immunoglobulin G 2FAPI-46 2Disulfides 2Cyclophosphamide 2Cetuximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Active not recruiting × avelumab × Clear all
NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Active not recruiting
22 enrolled
Dermatologic

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03244176 2024-07-30

AvR-CHOP

Austin Health

Phase EARLY_PHASE1 Active not recruiting
28 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡